



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00		A2	(11) International Publication Number: WO 00/58473 (43) International Publication Date: 5 October 2000 (05.10.00)																
(21) International Application Number: PCT/US00/08621 (22) International Filing Date: 31 March 2000 (31.03.00) (30) Priority Data: <table border="0"> <tr> <td>60/127,607</td> <td>31 March 1999 (31.03.99)</td> <td>US</td> </tr> <tr> <td>60/127,636</td> <td>2 April 1999 (02.04.99)</td> <td>US</td> </tr> <tr> <td>60/127,728</td> <td>5 April 1999 (05.04.99)</td> <td>US</td> </tr> <tr> <td>09/540,763</td> <td>30 March 2000 (30.03.00)</td> <td>US</td> </tr> </table>		60/127,607	31 March 1999 (31.03.99)	US	60/127,636	2 April 1999 (02.04.99)	US	60/127,728	5 April 1999 (05.04.99)	US	09/540,763	30 March 2000 (30.03.00)	US	(72) Inventors; and (75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US). (74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).					
60/127,607	31 March 1999 (31.03.99)	US																	
60/127,636	2 April 1999 (02.04.99)	US																	
60/127,728	5 April 1999 (05.04.99)	US																	
09/540,763	30 March 2000 (30.03.00)	US																	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications <table border="0"> <tr> <td>US</td> <td>60/127,607 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>31 March 1999 (31.03.99)</td> </tr> <tr> <td>US</td> <td>60/127,636 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 April 1999 (02.04.99)</td> </tr> <tr> <td>US</td> <td>60/127,728 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>5 April 1999 (05.04.99)</td> </tr> <tr> <td>US</td> <td>09/540,763 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>30 March 2000 (30.03.00)</td> </tr> </table>		US	60/127,607 (CIP)	Filed on	31 March 1999 (31.03.99)	US	60/127,636 (CIP)	Filed on	2 April 1999 (02.04.99)	US	60/127,728 (CIP)	Filed on	5 April 1999 (05.04.99)	US	09/540,763 (CIP)	Filed on	30 March 2000 (30.03.00)	(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US). Published Without international search report and to be republished upon receipt of that report.	
US	60/127,607 (CIP)																		
Filed on	31 March 1999 (31.03.99)																		
US	60/127,636 (CIP)																		
Filed on	2 April 1999 (02.04.99)																		
US	60/127,728 (CIP)																		
Filed on	5 April 1999 (05.04.99)																		
US	09/540,763 (CIP)																		
Filed on	30 March 2000 (30.03.00)																		
(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"																			
(57) Abstract <p>The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.</p>																			

	115		120		125	
Ser	Val	Ala	Asn	Lys	His	Gly
	130		135		140	
His	Gly	Phe	Arg	Asp	Leu	Arg
145			150		155	
Val	Asp	Met	Leu	Lys	Ser	His
			165		170	
Glu	Ala	Asp	Ala	Val	Tyr	Glu
	180		185		190	
Leu	Met	Lys	Cys	Ser	Leu	Asn
	195		200		205	
Ser	Met	Ala	Ala	Phe	Val	Pro
210			215		220	
Met	Leu	Gln	Ala	Ser	Thr	Ser
225			230		235	
Arg	Ala	Thr	Lys	Asp	Ser	Met
			245		250	
Met	Gly	Met	Thr	Asn	Leu	Glu
	260		265		270	
Glu	Asp	Val	Tyr	His	Thr	Val
	275		280		285	
Leu	Ala	Ser	Arg	Pro	Pro	Val
290			295		300	
Pro	Gly	Ala	His	Gln	Leu	Pro
305			310		315	
Lys	Tyr	Gly	Arg	Glu		
			325			

<210> 3727

<211> 630

<212> DNA

<213> Homo sapiens

<400> 3727

cggattcgag tcatacaagaa gaaaaagggtc attatgaaga agcgggaagaa gctaactcta
 60
 actcgcccca cccactggt gactgccggg ccccttgtga ccccaactcc agcaggggacc
 120
 ctcgaccccg ctgagaaaca agaaacaggc tgtcctcctt tgggtctgga gtccttgcca
 180
 gtttcagata gcgggcttga ggcacccagc agccagtcct ttggtcttgg accacaccga
 240
 ggacggctca acattcagtc aggcctggag gacggcgatc tatatgatgg agcctgggtgt
 300
 gctgaggagc agggacgccga tccatgggtt caggtggacg ctggggcacc caccgcttc
 360
 tcgggtgtta tcacacaggg caggaactct gtctggaggt atgactgggt cacatcatac
 420
 aaggtccagt tcagcaatga cagtcggacc tgggtgggaa gtaggaacca cagcagtggt
 480
 atggacgcag tatttcctgc caattcagac ccagaaactc cagtgtgaa cctcctgccc
 540
 gagccccagg tggcccgctt cattcgctg ctgccccaga cctgggtcca gggaggcgcg
 600

ccttgccctcc gggcagagat cctggcctgc
630

<210> 3728
<211> 210
<212> PRT
<213> Homo sapiens

<400> 3728
Arg Ile Arg Val Ile Lys Lys Lys Lys Val Ile Met Lys Lys Arg Lys
1 5 10 15
Lys Leu Thr Leu Thr Arg Pro Thr Pro Leu Val Thr Ala Gly Pro Leu
20 25 30
Val Thr Pro Thr Pro Ala Gly Thr Leu Asp Pro Ala Glu Lys Gln Glu
35 40 45
Thr Gly Cys Pro Pro Leu Gly Leu Glu Ser Leu Arg Val Ser Asp Ser
50 55 60
Arg Leu Glu Ala Ser Ser Ser Gln Ser Phe Gly Leu Gly Pro His Arg
65 70 75 80
Gly Arg Leu Asn Ile Gln Ser Gly Leu Glu Asp Gly Asp Leu Tyr Asp
85 90 95
Gly Ala Trp Cys Ala Glu Glu Gln Asp Ala Asp Pro Trp Phe Gln Val
100 105 110
Asp Ala Gly His Pro Thr Arg Phe Ser Gly Val Ile Thr Gln Gly Arg
115 120 125
Asn Ser Val Trp Arg Tyr Asp Trp Val Thr Ser Tyr Lys Val Gln Phe
130 135 140
Ser Asn Asp Ser Arg Thr Trp Trp Gly Ser Arg Asn His Ser Ser Gly
145 150 155 160
Met Asp Ala Val Phe Pro Ala Asn Ser Asp Pro Glu Thr Pro Val Leu
165 170 175
Asn Leu Leu Pro Glu Pro Gln Val Ala Arg Phe Ile Arg Leu Leu Pro
180 185 190
Gln Thr Trp Leu Gln Gly Gly Ala Pro Cys Leu Arg Ala Glu Ile Leu
195 200 205
Ala Cys
210

<210> 3729
<211> 1552
<212> DNA
<213> Homo sapiens

<400> 3729
naggaaacgc tttgtctgtc cggcaagccg acggcccgc gctggcctcc gtgacgcggg
60
cctctccgc gcctcgccgc atggagtaga aagggaccgc ggaagccga aagcgaaggc
120
atcaagttat cagcagatgt caaacattt gtcgccagat ttgccgggct caatgtggca
180
tggttagagt cctcagaagc atgtgtcttc ccagctctg cagccacata ctatccgttt
240
gttcaggaac caccagtgc agagcagaaa atatatactg aagacatggc ctttggagct
300

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n .
4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161.
5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprise the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is any integer 1-3161, or the complement thereof.
6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is a integer 1-3161, or the complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.

18. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected from the group consisting of:

- a) the nucleic acid of claim 1;
b) the polypeptide of claim 10; and
c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.